Creatine deficiency syndromes.

被引:14
|
作者
Cheillan, A
Cognat, S
Vandenberghe, N
Des Portes, V
Vianey-Saban, C
机构
[1] Hop Debrousse, Serv Biochim Pediat, F-69322 Lyon, France
[2] Hop Neurol & Neurochirurg P Wertheimer, Serv Neurol D, Lyon, France
[3] Ctr Hosp Lyon Sud, Serv Pediat, Lyon, France
关键词
creatine; guanidinoacetate; inborn errors of metabolism; mental retardation; speech delay;
D O I
10.1016/S0035-3787(05)85034-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction. Creatine deficiency syndromes are a newly described group of inborn errors of metabolism affecting creatine metabolism. Three diseases have been described. deficiency of arginine: glycine amidinotransferase (AGAT), deficiency of guanidinoacetate methyltransferase (GAMT) and creatine transporter defect (CRTR). State of art. These syndromes are characterized by a depletion of creatine/phosphocreatine in the brain. Clinically, most of the patients develop a variable mental retardation and a severe speech delay associated with epilepsy, extra-pyramidal syndrome and behavior disturbances. These diseases are often diagnosed during infancy but a few adult cases have been reported recently. Diagnosis is established by measurement of guanidinoacetate and creatine in biologic fluids and in vivo proton magnetic resonance spectroscopy by the total lack of intra-cerebral creatine/phosphocreatine demonstrating. GAMT and AGAT deficiencies are treatable by oral creatine supplementation whereas patients with CRTR do not respond to the treatment. Conclusion. Better knowledge of these syndromes is necessary to optimize diagnosis and patient management of these rare but potentially treatable disorders.
引用
收藏
页码:284 / 289
页数:6
相关论文
共 50 条
  • [31] Inherited Failure Syndromes.
    Bagby, Grover C., Jr.
    BLOOD, 2009, 114 (22) : 1577 - 1577
  • [32] Current and potential new treatment strategies for creatine deficiency syndromes
    Fernandes-Pires, Gabriella
    Braissant, Olivier
    MOLECULAR GENETICS AND METABOLISM, 2022, 135 (01) : 15 - 26
  • [33] Acute Coronary Syndromes.
    Damman, Peter
    Tijssen, Jan
    de Winter, Robbert
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (09): : 925 - 925
  • [34] Comorbidities and Myelodysplatic Syndromes.
    Naqvi, Kiran
    Garcia-Manero, Guillermo
    Sardesai, Sagar
    Oh, Jeong
    Pierce, Sherry
    Lei, Xiudong
    Suarez-Almazor, Maria E.
    BLOOD, 2009, 114 (22) : 1091 - 1091
  • [35] The biology of autistic syndromes.
    Treadwell-Deering, D
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2002, 41 (01): : 104 - 105
  • [36] Paraneoplastic rheumatic syndromes.
    Mitnick H.J.
    Current Rheumatology Reports, 2000, 2 (2) : 163 - 170
  • [37] Secondary parkinsonian syndromes.
    Fénelon, G
    REVUE NEUROLOGIQUE, 2003, 159 (05) : S39 - S49
  • [38] Megakaryopoiesis in myelodysplastic syndromes.
    Brereton, ML
    Adams, JA
    Briggs, M
    Yin, JAL
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 : 63 - 63
  • [39] On certain polyglandular syndromes.
    Crookshank, FG
    LANCET, 1912, 1 : 1716 - 1717
  • [40] Neurophysiology of parkinsonian syndromes.
    Defebvre, L
    Cassim, F
    REVUE NEUROLOGIQUE, 2003, 159 (05) : S62 - S74